查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601323

鐮狀細胞性貧血檢測和篩檢市場：按技術、年齡層和行業分類 - 2025-2030 年全球預測

Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography, Point-of-Care Tests), Age Group, Sector - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

鐮狀細胞性貧血檢測和篩檢市場2023年估值為94,395萬美元，預計2024年將達到10,7069萬美元，複合年成長率為13.51%，到2030年將達到22.2億美元。美元。

鐮狀細胞性貧血的檢測和篩檢主要涉及透過血紅蛋白電泳、高效液相層析(HPLC) 和基因檢測等血液檢測來識別鐮狀細胞疾病 (SCD) 和鐮狀細胞性狀 (SCT)。早期診斷的必要性強調了對這些檢查的必要性，以預防疼痛危象、中風和器官衰竭等嚴重併發症，從而改善患者的治療結果和生活品質。應用範圍從產前篩檢到新生兒檢測、帶因者檢測以及高風險個體的常規監測。最終用途範圍包括需要準確和快速診斷能力的醫療機構、研究機構和診斷實驗室。

主要市場統計
基準年[2023] 94395萬美元
預測年份 [2024] 10.7069億美元
預測年份 [2030] 2,293,220,000 美元
複合年成長率（%） 13.51%

市場成長受到遺傳疾病意識增強、政府新生兒篩檢計畫舉措以及基因檢測技術進步等因素的影響。由於高盛行率和不斷增加的醫療基礎設施投資，亞太和非洲的新興市場提供了巨大的商機。對公司的調查包括透過夥伴關係關係擴大其地理影響力、投資於非侵入性檢測的研究以及加強推廣計劃以提高意識。

然而，他們面臨低收入地區醫療保健設施有限、先進診斷技術成本高昂以及缺乏訓練有素的專業人員等挑戰。監管障礙也可能阻礙新測試的快速推出。為了克服這些問題，創新領域包括開發具有成本效益的攜帶式測試解決方案以及改善遠端醫療服務以服務偏遠地區的人。

研究方向可能包括專注於遺傳和分子診斷以及將 CRISPR 技術應用於確定性測試。持續的市場分析對於適應不斷變化的監管條件和患者需求至關重要。這個市場的特點是快速的技術創新和地區不同的醫療保健能力，需要靈活的商業策略來應對這些挑戰，同時利用成長機會。在這樣一個動態的環境中，公司需要投資教育宣傳活動、相關人員協作和適應性產品開發。

市場動態：快速發展的鐮狀細胞性貧血檢測和篩檢市場的關鍵市場洞察

供需的動態交互作用正在改變鐮狀細胞貧血檢測和篩檢市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球鐮狀細胞疾病流行
    • 政府持續努力支持診斷
    • 更多使用高效液相層析(HPLC) 檢測鐮狀細胞
  • 市場限制因素
    • 鐮狀細胞性貧血相關的診斷與治療問題
  • 市場機會
    • 開發深度學習框架，旨在對鐮狀細胞性貧血進行自動篩檢
    • 越來越注重開發非侵入式、手持式和數位技術
  • 市場挑戰
    • SCD 相關的臨床異質性和併發症
    • 資源匱乏，缺乏熟練的臨床實驗室技術人員

波特五力策略工具駕馭鐮狀性貧血檢測與篩檢市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解鐮狀性貧血檢測和篩檢市場的外部影響

外部宏觀環境因素在塑造鐮狀細胞貧血測試和篩檢市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解鐮狀貧血檢測和篩檢市場的競爭格局

鐮狀細胞性貧血測試和篩檢市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣鐮狀貧血測試和篩檢市場供應商的績效評估

FPNV 定位矩陣是評估鐮狀細胞性貧血測試和篩檢市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 鐮狀細胞疾病的全球盛行率
      • 政府繼續努力支持診斷
      • 高效液相層析(HPLC) 檢測鐮狀細胞疾病的重要用途
    • 抑制因素
      • 鐮狀細胞性貧血相關的診斷與治療問題
    • 機會
      • 開發鐮狀學習框架，旨在對鐮狀細胞性貧血進行自動篩檢
      • 更重視開發非侵入式、攜帶式和數位技術
    • 任務
      • SCD 相關的臨床異質性和併發症
      • 缺乏資源和熟練的臨床實驗室技術人員
  • 市場區隔分析
    • 技術：血紅蛋白電泳的持續進步，尤其是早期新生兒篩檢
    • 部門：企業實驗室處於創新和技術的前沿，提供全面的服務。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章鐮狀細胞性貧血檢測與篩檢市場：依技術分類

  • 血紅素電泳
    • 等電聚焦
  • 高效液相層析（HPLC）
  • 就地檢驗
    • 側流免疫檢測
    • 紙本快速診斷

鐮狀細胞性貧血檢測與篩檢市場：依年齡層

  • 成人篩檢
  • 新生兒篩檢
  • 第1年至第25年

第 8 章按產業分類的鐮狀細胞性貧血檢測與篩檢市場

  • 企業實驗室
  • 政府研究所
  • 私人實驗室
  • 官民合作關係

第9章美洲鐮狀細胞性貧血檢測與篩檢市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區鐮狀細胞貧血檢測與篩檢市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲鐮狀性貧血檢測與篩檢市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 授予 300 萬美元用於將血壓藥物重新用於 SCD 的研究
    • Mylab 推出獨特的照護現場快速鐮狀細胞貧血檢測
    • Lord's Mark Industries 與印度理工學院孟買分校合作在印度推廣鐮狀細胞檢測

公司名單

  • Biomedomics Inc.
  • HiMedia Laboratories
  • Pfizer Inc.
  • Silver Lake Research Corporation
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
  • Edvotek Inc.
  • Atlas Medical GmbH
  • Hemex Health
  • Quest Diagnostics Incorporated
  • CRISPR Therapeutics AG
  • Anamol Laboratories Pvt. Ltd.
  • Ulta Lab Tests, LLC
  • Bio-Rad Laboratories, Inc.
  • Bio Lab Diagnostics（I）Private Limited
  • PerkinElmer, Inc.
  • Bluebird bio, Inc.
  • Streck, Inc.
  • Maternova Inc.
  • Laboratory Corporation of America Holdings
  • Calibre Scientific, Inc.
  • PicnicHealth
  • Agios Pharmaceuticals, Inc.
Product Code: MRR-A339DAEFA37A

The Sickle Cell Anemia Testing & Screening Market was valued at USD 943.95 million in 2023, expected to reach USD 1,070.69 million in 2024, and is projected to grow at a CAGR of 13.51%, to USD 2,293.22 million by 2030.

Sickle Cell Anemia Testing and Screening encompasses a range of diagnostic techniques aimed at identifying sickle cell disease (SCD) and sickle cell trait (SCT), primarily through blood tests such as hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and genetic testing. The necessity of these tests is underscored by the need for early diagnosis to prevent severe complications like pain crises, stroke, and organ damage, thus improving patient outcomes and quality of life. Applications extend from prenatal screening to newborn and carrier testing and routine monitoring for individuals at risk. The end-use scope includes healthcare facilities, research institutions, and diagnostic laboratories that require precise and rapid diagnostic capabilities.

KEY MARKET STATISTICS
Base Year [2023] USD 943.95 million
Estimated Year [2024] USD 1,070.69 million
Forecast Year [2030] USD 2,293.22 million
CAGR (%) 13.51%

Market growth is influenced by factors such as increased awareness of genetic disorders, government initiatives for newborn screening programs, and technological advancements in genetic testing. Emerging markets in Asia-Pacific and Africa present substantial opportunities due to high prevalence rates and increasing healthcare infrastructure investments. Recommendations for businesses include expanding geographic presence through partnerships, investing in research for non-invasive testing methods, and enhancing outreach programs to raise awareness.

However, market growth faces challenges such as limited access to healthcare facilities in low-income regions, high costs of advanced diagnostic technologies, and lack of trained professionals. Regulatory hurdles can also impede the swift introduction of new testing methods. To overcome these, innovation areas include developing cost-effective, portable testing solutions and improving telehealth services to reach remote populations.

Research directions could focus on genetic and molecular diagnostics, exploring CRISPR technology for definitive tests. Continuous market analytics is crucial to adapt to changing regulatory landscapes and patient needs. The market, characterized by rapid technological change and varying regional healthcare capabilities, requires agile business strategies to address these challenges while capitalizing on growth opportunities. This dynamic environment calls for companies to invest in education campaigns, stakeholder collaborations, and adaptive product development.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sickle Cell Anemia Testing & Screening Market

The Sickle Cell Anemia Testing & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of Sickle Cell Disease Worldwide
    • Ongoing Government Initiatives to Support the Diagnosis
    • Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
  • Market Restraints
    • Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
  • Market Opportunities
    • Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
    • Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
  • Market Challenges
    • Clinical Heterogeneity and Complications Associated with SCD
    • Lack of Resources and Skilled Clinical Laboratory Workforce Shortages

Porter's Five Forces: A Strategic Tool for Navigating the Sickle Cell Anemia Testing & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sickle Cell Anemia Testing & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sickle Cell Anemia Testing & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sickle Cell Anemia Testing & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sickle Cell Anemia Testing & Screening Market

A detailed market share analysis in the Sickle Cell Anemia Testing & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sickle Cell Anemia Testing & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sickle Cell Anemia Testing & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Sickle Cell Anemia Testing & Screening Market, highlighting leading vendors and their innovative profiles. These include Biomedomics Inc., HiMedia Laboratories, Pfizer Inc., Silver Lake Research Corporation, Thermo Fisher Scientific Inc., Vertex Pharmaceuticals Incorporated, Edvotek Inc., Atlas Medical GmbH, Hemex Health, Quest Diagnostics Incorporated, CRISPR Therapeutics AG, Anamol Laboratories Pvt. Ltd., Ulta Lab Tests, LLC, Bio-Rad Laboratories, Inc., Bio Lab Diagnostics (I) Private Limited, PerkinElmer, Inc., Bluebird bio, Inc., Streck, Inc., Maternova Inc., Laboratory Corporation of America Holdings, Calibre Scientific, Inc., PicnicHealth, and Agios Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Sickle Cell Anemia Testing & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), and Point-of-Care Tests. The Hemoglobin Electrophoresis is further studied across Isoelectric focusing. The Point-of-Care Tests is further studied across Lateral Flow Immunoassay and Paper Based Rapid Diagnostics.
  • Based on Age Group, market is studied across Adult Screening, Newborn Screening, and Years 1 to 25.
  • Based on Sector, market is studied across Corporate Labs, Government Labs, Private Labs, and Public-Private-Partnerships.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Sickle Cell Disease Worldwide
      • 5.1.1.2. Ongoing Government Initiatives to Support the Diagnosis
      • 5.1.1.3. Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
    • 5.1.2. Restraints
      • 5.1.2.1. Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
      • 5.1.3.2. Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Clinical Heterogeneity and Complications Associated with SCD
      • 5.1.4.2. Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Ongoing advancements hemoglobin electrophoresis for initial screening particularly in newborns
    • 5.2.2. Sector: Corporate labs are at the forefront of innovation and technology to provide comprehensive services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Sickle Cell Anemia Testing & Screening Market, by Technology

  • 6.1. Introduction
  • 6.2. Hemoglobin Electrophoresis
    • 6.2.1. Isoelectric focusing
  • 6.3. High-performance Liquid Chromatography (HPLC)
  • 6.4. Point-of-Care Tests
    • 6.4.1. Lateral Flow Immunoassay
    • 6.4.2. Paper Based Rapid Diagnostics

7. Sickle Cell Anemia Testing & Screening Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult Screening
  • 7.3. Newborn Screening
  • 7.4. Years 1 to 25

8. Sickle Cell Anemia Testing & Screening Market, by Sector

  • 8.1. Introduction
  • 8.2. Corporate Labs
  • 8.3. Government Labs
  • 8.4. Private Labs
  • 8.5. Public-Private-Partnerships

9. Americas Sickle Cell Anemia Testing & Screening Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sickle Cell Anemia Testing & Screening Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sickle Cell Anemia Testing & Screening Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. USD 3 million awarded to study repurposing of blood pressure drug for SCD
    • 12.3.2. Mylab introduces indigenous Point-of-care, Rapid Sickle Cell Anemia Test
    • 12.3.3. Lord's Mark Industries, IIT-Bombay partner to advance sickle cell testing in India

Companies Mentioned

  • 1. Biomedomics Inc.
  • 2. HiMedia Laboratories
  • 3. Pfizer Inc.
  • 4. Silver Lake Research Corporation
  • 5. Thermo Fisher Scientific Inc.
  • 6. Vertex Pharmaceuticals Incorporated
  • 7. Edvotek Inc.
  • 8. Atlas Medical GmbH
  • 9. Hemex Health
  • 10. Quest Diagnostics Incorporated
  • 11. CRISPR Therapeutics AG
  • 12. Anamol Laboratories Pvt. Ltd.
  • 13. Ulta Lab Tests, LLC
  • 14. Bio-Rad Laboratories, Inc.
  • 15. Bio Lab Diagnostics (I) Private Limited
  • 16. PerkinElmer, Inc.
  • 17. Bluebird bio, Inc.
  • 18. Streck, Inc.
  • 19. Maternova Inc.
  • 20. Laboratory Corporation of America Holdings
  • 21. Calibre Scientific, Inc.
  • 22. PicnicHealth
  • 23. Agios Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SICKLE CELL ANEMIA TESTING & SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ISOELECTRIC FOCUSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PAPER BASED RAPID DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY ADULT SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY YEARS 1 TO 25, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY CORPORATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY PUBLIC-PRIVATE-PARTNERSHIPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY POINT-OF-CARE TESTS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM SICKLE CELL ANEMIA TESTING & SCREENING MARKET SIZE, BY SECTOR, 2018-2030 (USD MILLION)
  • TABLE 234. SICKLE CELL ANEMIA TESTING & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. SICKLE CELL ANEMIA TESTING & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023